共 79 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424
[2]
Ferlay J(2019)Hepatocellular carcinoma N Engl J Med. 380 1450-1462
[3]
Soerjomataram I(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med. 359 378-390
[4]
Siegel RL(2016)Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) J Clin Oncol. 34 192-192
[5]
Torre LA(2015)Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial J Clin Oncol. 33 172-179
[6]
Jemal A(2015)SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma J Clin Oncol. 33 559-566
[7]
Villanueva A(2013)Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study J Clin Oncol. 31 3517-3524
[8]
Llovet JM(2013)Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial J Clin Oncol. 31 4067-4075
[9]
Ricci S(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet. 391 1163-1173
[10]
Mazzaferro V(2013)Sorafenib in patients with Child–Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis Ann Oncol. 24 406-411